Last week saw the publication of the UK's Accelerated Access Review, containing proposals to cut four years from the drug development process – but AstraZeneca seems unconvinced that access
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh